You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Insulin Receptor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Insulin Receptor Mutation, Partial Lipodystrophy Trial run by the National Institute of Diabetes and Digestive and Kidney

Not yet recruiting
  • Insulin Receptor Mutation
  • Partial Lipodystrophy
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

Type 2 Diabetes Trial in Nanjing (Add oral hyppoglycemia drug, Add GLP-1 receptor agonist, Change insulin)

Recruiting
  • Type 2 Diabetes Mellitus
  • Add oral hyppoglycemia drug
  • +2 more
  • Nanjing, China
    Nanjing First Hospital, Nanjing Medical Univesity
Oct 11, 2022

Diabetes, Diabetic Kidney Disease Trial in Sha Tin (Dulaglutide, Insulin Degludec, Continuous glucose monitor)

Recruiting
  • Diabetes Mellitus
  • Diabetic Kidney Disease
  • Sha Tin, Hong Kong
    Prince of Wales Hospital
Nov 8, 2022

Aging, Diabetes, Type 2, PreDiabetes Trial in San Antonio (Semaglutide Injectable Product, Lifestyle Counseling)

Recruiting
  • Aging
  • +3 more
  • Semaglutide Injectable Product
  • Lifestyle Counseling
  • San Antonio, Texas
    UT Health San Antonio
Apr 3, 2023

AR, IGF-IR, IR and Peripheral Artery Disease

Recruiting
  • Androgen Receptor Abnormal
  • +2 more
  • arterial reconstructive open surgery
  • Catanzaro, Italy
    University Magna Graecia of Catanzaro
Jan 12, 2021

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal Trial in Los Angeles, Bethesda (Dasatinib, Ganitumab)

Terminated
Has Results
  • Rhabdomyosarcoma
  • +2 more
  • Los Angeles, California
  • +1 more
Mar 17, 2022

Overweight and Obesity, Insulin Resistance Trial in Columbia (Placebo - Cap, Amiloride Pill)

Recruiting
  • Overweight and Obesity
  • Insulin Resistance
  • Placebo - Cap
  • Amiloride Pill
  • Columbia, Missouri
    University of Missouri Hospital and Clinics
May 19, 2022

A Pan-European Post-Authorisation Safety Study: Risk of

Not yet recruiting
  • Pancreatic Cancer
  • Exenatide
  • Non-GLP-1 RA based glucose lowering drugs
  • (no location specified)
Dec 21, 2022

Type2 Diabetes Trial in Duesseldorf (AP-325, Placebo matching AP-325)

Recruiting
  • Type2 Diabetes
  • Duesseldorf, NRW, Germany
    German Diabetes Center
Jan 5, 2022

Type 2 Diabetes, Glucose Tolerance Impaired, Insulin Sensitivity Trial in San Antonio (REMD-477, Placebo Subcutaneous injection)

Recruiting
  • Type 2 Diabetes
  • +2 more
  • San Antonio, Texas
    Texas Diabetes Institute
Dec 22, 2021

Pre-frail Elderly Trial in Jakarta (Cholecalciferol, Placebo)

Completed
  • Pre-frail Elderly
  • Jakarta, DKI Jakarta, Indonesia
    Cipto Mangunkusumo General Hospital
Jan 25, 2023

Obesity, Liver Diseases, Liver Fibrosis Trial in Boston (ESG, GLP1-RA)

Not yet recruiting
  • Obesity
  • +16 more
  • Boston, Massachusetts
    Brigham and Women's Hospital
Nov 14, 2023

GLP-1 Receptor Agonists on Efficacy and Persistence, Adherence

Completed
  • Type 2 Diabetes
  • Obesity
  • Valencia, Spain
    INCLIVA
Sep 6, 2022

Diabetes Type 2 in Obese, Inflammation, Metabolic Disease Trial in Basel (Anakinra Prefilled Syringe)

Recruiting
  • Diabetes Mellitus Type 2 in Obese
  • +3 more
  • Anakinra Prefilled Syringe
  • Basel, Basel BS, Switzerland
    University Hospital Basel
Sep 7, 2021

Rheumatoid Arthritis Trial in Sao Paulo (Exercise)

Recruiting
  • Rheumatoid Arthritis
  • Exercise
  • Sao Paulo, Brazil
    Univsersity of Sao Paulo
Aug 23, 2021

Type2 Diabetes Trial in Hellerup (Placebo, GIP receptor antagonization)

Active, not recruiting
  • Type2 Diabetes
  • Placebo
  • GIP receptor antagonization
  • Hellerup, Capital Region, Denmark
    Center for Clinical Metabolic Research, Gentofte Hospital
Sep 16, 2021

Type 2 Diabetes Trial in Naples (IDegLira, IGlarLixi, Insulin/Canaglifozin)

Completed
  • Type 2 Diabetes
  • Naples, Italy
    Unit of Endocrinology and Metabolic Diseases
Oct 20, 2020

Type 2 Diabetes Trial in Copenhagen (Endurance exercise training, Semaglutide)

Recruiting
  • Type 2 Diabetes
  • Copenhagen, Denmark
    Xlab, Center for Healthy Aging, Department of Biomedical Science
Feb 8, 2021

Type 2 Diabetes Trial in Fresno (GLP1 receptor agonist, basal insulin, SGLT2 inhibitor)

Completed
Has Results
  • Type 2 Diabetes Mellitus
  • GLP1 receptor agonist
  • +3 more
  • Fresno, California
    UCSF Fresno
Oct 20, 2020

Insulin Resistance, Diabetes, Abnormal Glucose Metabolism Trial run by the NIDDK (Liothyronine)

Completed
Has Results
  • Insulin Resistance
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Nov 12, 2019

HbA1c Among Type 2 Diabetes Newly Initiating GLP1RAs vs Basal

Unknown status
  • Diabetes Mellitus, Type 2
  • Boston, Massachusetts
    Brigham and Women's Hospital
Jul 7, 2020

Second Line Therapy Medications in Diabetes

Recruiting
  • Diabetes Mellitus, Type 2
  • Wilmington, Delaware
  • +4 more
Dec 22, 2021

Malignant Glioma, Tumors Trial in Philadelphia (IGF-1R/AS ODN; Surgery with tissue harvest and implantation 20 diffusion

Completed
  • Malignant Glioma
  • Neoplasms
  • IGF-1R/AS ODN; Surgery with tissue harvest and implantation 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.
  • Philadelphia, Pennsylvania
    Thomas Jefferson University Hospital
Oct 5, 2020

Diabetes, Type 2 Trial in Kuwait (GLP-1 receptor agonist)

Recruiting
  • Diabetes Mellitus, Type 2
  • GLP-1 receptor agonist
  • Kuwait, Kuwait
    Dasman Diabetes Institute
Jul 19, 2020

Breast Cancer, Hyperinsulinism, HER2-negative Breast Cancer Trial in New Haven (Dapagliflozin 10mg)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Dapagliflozin 10mg
  • New Haven, Connecticut
    Yale Cancer Center Smilow Cancer Hospital
Aug 3, 2023